- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00371397
Yoga, Immune Function, and Health
June 6, 2016 updated by: Janice Kiecolt-Glaser, Ohio State University
Psychoneuroimmunology and Mind-Body Interventions
This study is designed to examine the impact of hatha yoga on immune and hormonal functioning in healthy individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is designed to examine the effects of hatha yoga on autonomic, immune, and endocrine function.
The data from both inexperienced and experienced groups will help us better understand how longer-term practice of yoga may be beneficial.
The study consists of one 3-hour screening session and three 6-hour activity sessions with 30 minute follow-up appointments the following morning scheduled 2 - 4 weeks apart.
Each participant will complete the 3 activity sessions, which will consist of either yoga, mild movement, or a neutral activity (watching a videotape), in randomly assigned order.
Thus, both novices and experts will participate in 3 activity sessions each (yoga, movement control, video control).
The order in which each participant goes through the activity sessions is counterbalanced.
Data for each activity session will be aggregated by group (i.e.
novice or expert).
We will measure responses to tape stripping to assess skin barrier repair, and evaluate responses to computer tasks, self-report measures, and a battery of unobtrusive behavioral measures.
We will also collect blood and saliva samples to measure immune and endocrine outcomes.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- healthy female adults
- relatively inexperienced with yoga (beginner)
- experienced with yoga (advanced practitioner)
Exclusion Criteria:
- Treatment with medication that has immunological or endocrinological consequences
- Chronic health problems that affect immune or endocrine systems
- Anemia
- Use of psychoactive drugs or mood-altering medication
- Smoking
- Needle or blood phobias
- Tape or bandage allergies
- Pregnancy or nursing within the previous 3 months
- Heart problems
- History of hip or knee replacement surgery, displaced vertebrae, and any other physical limitations that would prevent full participation in the program
- use of statins, beta blockers
- excessive alcohol use
- convulsive disorders
- Body Mass Index (BMI) ≥ 30.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hatha yoga classes
Groups consisted of novices or experts.
Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
|
Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs.
The yoga activity sessions were directed by four experienced yoga teachers following a script.
The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose).
Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
|
|
Sham Comparator: Movement Control
Non-Hatha yoga gentle movement.
Groups consisted of novices or experts.
Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
|
Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session.
To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
|
|
No Intervention: Passive Video Control
Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics.
Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Detectable C-Reactive Protein (CRP)
Time Frame: 8:30 a.m. at each of the three visits, scheduled at least 2 weeks apart
|
High sensitivity C-reactive protein (hsCRP) assessed once at baseline, at each of the three visits.
The hsCRP assay was performed using chemiluminescence methodology with the Immulite 1000 (Siemens Medical Solutions, Los Angeles, Ca.)
The lowest level of detection is .3
mg/dL.
43% of the values were below this lower bound, thus hsCRP was dichotomized as undetectable/detectable.
|
8:30 a.m. at each of the three visits, scheduled at least 2 weeks apart
|
|
Cortisol
Time Frame: Day 1 8:30, 10:05, 10:58, 11:35, 12:05, 13:10. Day 2 7:30
|
All cortisol and catecholamine samples for a subject were frozen after collection and analyzed within the same assay run after the participant had completed the study.
|
Day 1 8:30, 10:05, 10:58, 11:35, 12:05, 13:10. Day 2 7:30
|
|
Skin Barrier Repair: Trans-epidermal Water Loss (TEWL)
Time Frame: 11:50, 12:50 at each of the three visits, scheduled at least 2 weeks apart
|
Cellophane tape stripping, a common dermatological paradigm for studying restoration of the skin barrier, was used to examine whether the time necessary for recovery from minor physical insults varied by condition or yoga expertise.
Measurement of the rate of transepidermal water loss (TEWL) through human skin provides a noninvasive method to monitor changes in the skin's barrier function.
TEWL was measured twice during the session using a computerized evaporimetry instrument, the DermaLab® (CyberDERM, Media, PA), and barrier recovery was calculated.
|
11:50, 12:50 at each of the three visits, scheduled at least 2 weeks apart
|
|
Immune Function: Soluble Interleukin-6 Receptor (sIL-6r)
Time Frame: Day 1 8:30, 11:35, 13:10. Day 2 7:30
|
Serum levels of the sIL-6r were assayed using Quantikine High Sensitivity Immunoassay kits (R&D), per kit instructions.
|
Day 1 8:30, 11:35, 13:10. Day 2 7:30
|
|
Immune Function: Tumor Necrosis Factor-alpha (TNF-α)
Time Frame: Day 1 8:30, 11:35, 13:10. Day 2 7:30
|
Serum levels of TNF-α were assayed using Quantikine High Sensitivity Immunoassay kits (R&D), per kit instructions.
|
Day 1 8:30, 11:35, 13:10. Day 2 7:30
|
|
Immune Function: Lipopolysaccharide (LPS) -Stimulated Production of Interleukin-6 (IL-6)
Time Frame: Day 1 8:30, 10:05, 11:35, 13:10. Day 2 7:30
|
Supernatants from PBLs stimulated with 5μg/ml lipopolysaccharide (LPS) for 72 h were assayed for IL-6 and TNF-α using ELISA kits (B-D Pharmingen).
|
Day 1 8:30, 10:05, 11:35, 13:10. Day 2 7:30
|
|
Immune Function: LPS-stimulated Production of TNF-α
Time Frame: Day 1 8:30, 10:05, 11:35, 13:10. Day 2 7:30
|
Supernatants from PBLs stimulated with 5μg/ml lipopolysaccharide (LPS) for 72 h were assayed for IL-6 and TNF-α using ELISA kits (B-D Pharmingen).
|
Day 1 8:30, 10:05, 11:35, 13:10. Day 2 7:30
|
|
Immune Function: Interleukin-6 (IL-6)
Time Frame: Day 1 8:30, 11:35, 13:10. Day 2 7:30
|
Serum levels of TNF-α, IL-6, and the sIL-6r were assayed using Quantikine High Sensitivity Immunoassay kits (R&D), per kit instructions
|
Day 1 8:30, 11:35, 13:10. Day 2 7:30
|
|
Catecholamine Production: Epinephrine
Time Frame: 8:30, 10:05, 10:28, 10:58, 11:35, 12:05 at each of the three visits, scheduled at least 2 weeks apart
|
All cortisol and catecholamine samples for a subject were frozen after collection and analyzed within the same assay run after the participant had completed the study.
|
8:30, 10:05, 10:28, 10:58, 11:35, 12:05 at each of the three visits, scheduled at least 2 weeks apart
|
|
Catecholamine Production: Norepinephrine
Time Frame: 8:30, 10:05, 10:28, 10:58, 11:35, 12:05
|
All cortisol and catecholamine samples for a subject were frozen after collection and analyzed within the same assay run after the participant had completed the study.
|
8:30, 10:05, 10:28, 10:58, 11:35, 12:05
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart Rate
Time Frame: Day 1: 8:30, 9:15, 9:45, 10:00, 10:45, 11:35, 12:05, 12:15
|
Day 1: 8:30, 9:15, 9:45, 10:00, 10:45, 11:35, 12:05, 12:15
|
|
|
Blood Pressure
Time Frame: 7:55 at each of the three visits, scheduled at least 2 weeks apart
|
7:55 at each of the three visits, scheduled at least 2 weeks apart
|
|
|
Mood: Positive and Negative Affect Schedule (PANAS)Positive
Time Frame: 7:35, 11:45, 12:30 at each of the three visits, scheduled at least 2 weeks apart
|
The Positive and Negative Affect Schedule (PANAS) includes two 10-item mood scales.
Each item is rated on a 5-point scale ranging from 1 = very slightly or not at all to 5 = extremely, to indicate the extent to which the respondent has felt this way in the indicated time frame.
Several additional words were added to better capture low positive affect: happy, satisfied, disappointed, discouraged, low, sad.
|
7:35, 11:45, 12:30 at each of the three visits, scheduled at least 2 weeks apart
|
|
Mood: Positive and Negative Affect Schedule (PANAS)Negative
Time Frame: 7:35, 11:45, 12:30 at each of the three visits, scheduled at least 2 weeks apart
|
The Positive and Negative Affect Schedule (PANAS) includes two 10-item mood scales.
Each item is rated on a 5-point scale ranging from 1 = very slightly or not at all to 5 = extremely, to indicate the extent to which the respondent has felt this way in the indicated time frame.
Several additional words were added to better capture low positive affect: happy, satisfied, disappointed, discouraged, low, sad.
|
7:35, 11:45, 12:30 at each of the three visits, scheduled at least 2 weeks apart
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Janice K. Kiecolt-Glaser, PhD, Ohio State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
September 1, 2008
Study Completion (Actual)
September 1, 2008
Study Registration Dates
First Submitted
August 31, 2006
First Submitted That Met QC Criteria
August 31, 2006
First Posted (Estimate)
September 4, 2006
Study Record Updates
Last Update Posted (Estimate)
July 6, 2016
Last Update Submitted That Met QC Criteria
June 6, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2005H0068
- R21AT002971-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.